Show simple item record

dc.contributor.authorJakharia, Niyati
dc.contributor.authorHoward, Dianna
dc.contributor.authorRiedel, David J
dc.date.accessioned2021-07-28T15:02:04Z
dc.date.available2021-07-28T15:02:04Z
dc.date.issued2021-07-21
dc.identifier.urihttp://hdl.handle.net/10713/16252
dc.description.abstractPurpose of review: Cytomegalovirus (CMV) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (Allo-HSCT). New strategies and methods for prevention and management of CMV infection are urgently needed. We aim to review the new developments in diagnostics, prevention, and management strategies of CMV infection in Allo-HSCT recipients. Recent findings: The approval of the novel anti-CMV drug letermovir in 2017 has led to an increase in the use of antiviral prophylaxis as a preferred approach for prevention in many centers. Real-world studies have shown efficacy similar to the clinical trial. CMV-specific T cell-mediated immunity assays identify patients with immune reconstitution and predict disease progression. Phase 2 trials of maribavir have shown its efficacy as preemptive therapy and treatment of resistant and refractory CMV infections. Adoptive T cell therapy is an emerging option for treatment of refractory and resistant CMV. Of the different CMV vaccine trials, PepVax has shown promising results in a phase 1 trial. Summary: CMV cell-mediated immunity assays have potential to be used as an adjunctive test to develop individualized management plan by identifying the patients who develop immune reconstitution; however, further prospective interventional studies are needed. Maribavir and adoptive T cell therapy are promising new therapies for treatment of CMV infections. CMV vaccine trials for prevention are also under way.en_US
dc.description.urihttps://doi.org/10.1007/s40506-021-00253-wen_US
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc8294301/en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofCurrent Treatment Options in Infectious Diseasesen_US
dc.rights© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.en_US
dc.subjectCMV infectionen_US
dc.subjectHematopoietic stem cell transplantationen_US
dc.subjectLetermoviren_US
dc.titleCMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategiesen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s40506-021-00253-w
dc.identifier.pmid34305463
dc.source.beginpage1
dc.source.endpage18
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record